An Estimated 1,000 Global Cannabis Industry Senior Decision Makers To Take Part In CannX Tel Aviv 2019 Conference

The International Cannabis Business Conference would like to encourage international cannabis entrepreneurs and cannabis enthusiasts to check out the upcoming International Medical Cannabis Conference (CannX). Below is more information about the event:

The international medical cannabis conference focusing on business, technology and agriculture will take place for the fourth year in a row on September 9-10.

The conference will include a politics session focusing on the issue of medical cannabis and the upcoming election campaign.

Conference speakers will include:

• CannX Chairman Prof. Raphael Mechoulam, THC Cannabinoid Trailblazer and Israel Prize Recipient
• Kevin Roland, Director, Canopy Growth Corporation, Canada
• Philippe Lucas, VP, Global Patient Research & Access, Tilray, Canada
• Jonathan Page, Chief Science Officer, Aurora Cannabis Inc., Canada
• Steve Hawkins, President and CEO of Horizons ETFs,Canada
• Ziva Eger, Chief Executive of Foreign Investments & Industrial Co-operation, Israel
• Minister of Agriculture Uri Ariel
• Prof. Arnon Afek, Acting Chief Physician, Israeli Medical Cannabis Agency, Ministry of Health and former Director General of the Ministry of Health
• Itai Malchior, Head of the Inter-Ministerial Committee for the Export of Medicinal Cannabis, Foreign Trade Administration, Ministry of Economy & Industry

The 4th International Medical Cannabis Conference (CannX) will take place on 9-10 September at the Expo Tel Aviv venue. The CannX experience has been refined to offer some of the most effective networking in the business and access to key opinion leaders. An estimated 1,000 senior decision makers from the entire global cannabis industry value chain are expected to participate in the international conference. Among them entrepreneurs, investors, growers, physicians, researchers, senior decision makers in medical cannabis companies, pharmacists and patients.

The conference will take place for the 4th consecutive year in partnership with Cann10, which manufactures and markets medical cannabis products and technologies and Kenes, a professional conference organizer.

CannX is the only medical cannabis conference which is accredited as a scientific conference by the European Accreditation Council for Continuing Medical Education (EACCME). This year, attendees at CannX will enjoy a more dynamic and interactive program – allowing them to participate directly in debates and discussions.

Within the main conference topics:

September 9 (Monday):

10:00 OPENING SESSION’ Uri Ariel, Minister of Agriculture

10:15 OPENING SESSION, Yossi Bornstein, Founder, Partner and Owner, Cann10, Founder, Shizim Group, Biomed holding group.

10:30 KEYNOTE LECTURE: THE CANNABINOID SYSTEM: WHERE DO WE STAND TODAY? Prof. Raphael Mechoulam, CannX Chairman, THC Cannabinoid Trailblazer and Israel Prize Recipient

11:30 SESSION: CANNABIS AND THE OPIOD EPIDEMIC, Chair: Elyad Davidson, Director, Pain Relief Unit at Hadassah Hebrew University Medical Center, Israel; David Casarett, Prof. Chief of Palliative Care, Duke University, USA; Philippe Lucas, VP of Patient Research and Access, Tilray, Canada

12:20 SESSION: THE ISRAEL MODEL: A SMALL COUNTRY, A LEADING INDUSTRY, Chair: Kobi Caspi, Co-founder and CFO, Cann10, Israel, Karina Rubinstein, Director of Business Development, Start Up Division at Israel Innovation Authority, Israel; Ziva Eger, Chief Executive of Foreign Investments & Industrial Cooperation; Amir Goldstein, Chief Operations
Officer, IMC, Israel; Tal Ben David, Head Pharmacist, GreenPharma, Israel; Liron Goldshtein, Head, Cannabis Pharmacy Dept., GreenPharma, Israel

12:20 SESSION: CANNABIS GENETICS – NEW DEVELOPMENTS, Chair: Shay Avraham Sarid, Co-Founder & CTO, Seach Medical Cannabis Group, Israel; Jonathan Page, Chief Scientist, Aurora Cannabis Inc., Canada; Arnon Heyman, CEO, Canonic Ltd., Israel

14:30 SESSION: THE IMPACT OF CANNABIS-BASED TREATMENT ON VARIOUS DISEASES – PRE-CLINICAL AND CLINICAL RESULTS, Chair: Reuven Or, Prof MD Cancer Immunotherapy & Immunobiology Research Center, Hadassah University Hospital, Israel; Yossi Tam (ENDOCANNABINOID SYSTEM IN HUMAN PHYSIOLOGY); Gurmit Singh (CBDA-ME AND PERIPHERAL NEUROPATHIC PAIN); Ruth Djaldetti (CANNABIS AND PARKINSON); Vered Hermush (DEMENTIA AND CANNABIS); Avi Priel (PAIN AND IONOTROPIC CANNABINOIDS RECEPTORS); Reuven Or and Osnat Almogi-Hazan (CANNABIS IN
CANCER)

14:30 SESSION: DIGITAL HEALTH AND CANNABIS – IS THE FUTURE HERE? BIG DATA, PREDICTION, AND ARTIFICIAL INTELLIGENCE, Chair: Gali Weinreb, Editor and Biomed correspondent, Globes, Israel; Itzhak Kurek, CEO and Co-Founder, Cannformatics Inc., USA; David Berg, President and CTO, Strainprint Technologies Ltd., Canada; Avihu Tamir, CEO, Kanabo Research, Israel

September 10 (Tuesday):

10:00 SESSION: ENTERING THE PHARMACEUTICAL INDUSTRY – HOW TO MEET PHARMA STANDARDS IN CANNABIS BASED PRODUCTS, Arnon Afek, Associate Director General, Sheba Medical Center, Acting Chief Physician, Israeli Medical Cannabis Agency, Ministry of Health, Israel; Kevin Roland, Director, CMC (Chemical Manufacturing Controls), Canopy Health Innovation, Canopy Growth Corporation, Canada; Patrick Schmitt, Molecular biologist, Co-Founder and Chief Science Officer, Farmako, Germany; Ianiv Eisenscher, Chief Product Officer, Syqe Medical, Israel; Orna Dreazen, CEO and Chairperson of the Board of Directors, Nextar Chempharma Solutions Ltd., Israel

12:00 DECISION-MAKERS PANEL – THE POLITICAL ANGLE OF THE MEDICAL CANNABIS FIELD; Moderator: Dafna Liel, Channel 12 Knesset Correspondent, Politician panelists participating will be disclosed later on.

14:00 SESSION: GLOBAL TRADE: OVERCOMING IMPORT-EXPORT BARRIERS IN A CONSTANTLY CHANGING REGULATORY ENVIRONMENT, Moderator: Lior Kenan, Chanel 13 Economics Correspondent, Israel; Itai Melchior, Senior Project Manager at Foreign Trade Administration – Ministry of Economy and Industry, Israel; Elizabeth Hatchuel, Adjunct Professor, Universidade Federal Rural do Rio de Janeiro, Brazil

16:00 SESSION: THE MEDICAL CANNABIS CAPITAL MARKET – AN ECONOMIC BUBBLE OR THE REAL THING? Moderator: Sophie Shulman, Capital Markets Editor, Calcalist, Israel, Steve Hawkins, President and CEO, Horizons ETFs, Canada; Shiry Eden, Founder and CEO, Nishot, Israel; Brenda Smith, CEO & Founder, CB Capital Concierge, Inc., USA; Ilan Gerzi, Adv., Senior Partner and Head of the Capital Markets Department, Pearl Cohen, Israel

Ori Alperovitz, Cann10 CEO: “In the past decade, medical cannabis has gone through a dramatic image shift, from a dangerous drug to a legitimate plant with unique medical qualities which have yet to be fully exposed. Every year, the CannX conference draws hundreds of senior decision makers from the entire global cannabis industry value chain, who are thirsty for sources of knowledge and new investment channels within this field, to Israel.

A young and constantly evolving field, the global cannabis industry is going through frequent changes due to changing regulatory policies and scientific breakthroughs created by the medical community. Our Cann10 accelerator is always on the lookout for smart, personalized cannabis technologies spearheading the innovative cannabis arena worldwide.

Cann10 Background:

Cann10 is an international company for development and marketing of medical cannabis products and innovative technological entrepreneurship within this field. Cann10 owns and distributes the “Cannareet” brand sold in Israeli pharmacies within the new medical cannabis regulations (30% market share). Among company activities in Israel and abroad: development and promotion of medical cannabis startups within the CannXL accelerator; management of a medical cannabis entrepreneurship course in collaboration with the Technion (Israel Institute of Technology); entrepreneurship and management of scientific, technological and business conferences within the medical cannabis field in Israel and other parts of the world; partnership in factory and breeding farm establishment in a number of countries.